Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
Cymabay Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 26, 2019
Cymabay Therapeutics reported fiscal year 2018 executive compensation information on April 26, 2019.
In 2018, five executives at Cymabay Therapeutics received on average a compensation package of $1.8M, a 10% decrease compared to previous year.
Average pay of disclosed executives at Cymabay Therapeutics
Paul Quinlan, General Counsel, received $3M in total. 82% of Quinlan's compensation, or $2.4M, was in option awards. Quinlan also received $158K in bonus, $376K in salary, as well as $4.2K in other compensation.
Sujal Shah, Chief Executive Officer, received a compensation package of $1.9M, which decreased by 62% compared to previous year. 63% of the compensation package, or $1.2M, was in option awards.
Charles A. McWherter, Chief Scientific Officer, earned $1.8M in 2018, a 153% increase compared to previous year.
Pol Boudes, Chief Medical Officer, received $1.6M in 2018, which increases by 112% compared to 2017.
Daniel Menold, Vice President, Finance, earned $857K in 2018.
Related executives
You may also like
Source: SEC filing on April 26, 2019.